Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5739169 | 0.90 | F10 (0.51) | F10F2ITGB3ITGA2B | |
| SCHEMBL5737375 | 0.88 | F10 (0.52) | F10ABCB11 | |
| SCHEMBL5737890 | 0.85 | F10 (0.48) | F10 | |
| SCHEMBL5739322 | 0.83 | F10 (0.49) | F10F2ITGB3ITGA2B | |
| SCHEMBL5737363 | 0.83 | F10 (0.48) | F10F2 | |
| SCHEMBL5763117 | 0.82 | F10 (0.54) | F10F2ABCB11ST14 | |
| SCHEMBL9815512 | 0.81 | F10 (0.64) | F10F2 | |
| SCHEMBL6619705 | 0.78 | F10 (0.47) | F10F2ABCB11ST14 | |
| SCHEMBL9815515 | 0.77 | F10 (0.51) | F10F2ABCB11ST14 | |
| SCHEMBL5221102 | 0.77 | F10 (0.46) | F10F2ABCB11ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660488-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | GORDEEV MIKHAIL FEDOROVICH (US) | 2005-03-24 | — | — | US | claimed |
| WO-2005019214-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1660488-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | GORDEEV MIKHAIL FEDOROVICH (US) | 2005-03-24 | — | — | US | disclosed |
| WO-2005019214-A1 | NOVEL ANTIMICROBIAL ARYLOXAZOLIDINONE COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065187-A1 | Novel antimicrobial aryloxazolidinone compounds | XDH, NQO1, MPO | F10 4687/4885F2 3341/4885ABCB11 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.